| Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis LM Spring, G Fell, A Arfe, C Sharma, R Greenup, KL Reynolds, BL Smith, ... Clinical cancer research 26 (12), 2838-2848, 2020 | 541 | 2020 |
| Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape E Marco, RL Karp, G Guo, P Robson, AH Hart, L Trippa, GC Yuan Proceedings of the National Academy of Sciences 111 (52), E5643-E5650, 2014 | 276 | 2014 |
| Prognostic role of circulating exosomal miRNAs in multiple myeloma. SM others Blood 129 (17), 2429--2436, 2017 | 262* | 2017 |
| Adaptive platform trials: definition, design, conduct and reporting considerations Nature Reviews Drug Discovery 18 (10), 797-807, 2019 | 240 | 2019 |
| On the restricted mean survival time curve in survival analysis L Zhao, B Claggett, L Tian, H Uno, MA Pfeffer, SD Solomon, L Trippa, ... Biometrics 72 (1), 215-221, 2016 | 229 | 2016 |
| Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples M Riester, W Wei, L Waldron, AC Culhane, L Trippa, E Oliva, S Kim, ... Journal of the National Cancer Institute 106 (5), dju048, 2014 | 219 | 2014 |
| A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma EK O'Donnell, JP Laubach, AJ Yee, T Chen, CA Huff, FG Basile, ... British journal of haematology 182 (2), 222-230, 2018 | 157 | 2018 |
| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 138 | 2020 |
| Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer HA Parsons, J Rhoades, SC Reed, G Gydush, P Ram, P Exman, K Xiong, ... Clinical Cancer Research 26 (11), 2556-2564, 2020 | 131 | 2020 |
| The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? AM Vanderbeek, R Rahman, G Fell, S Ventz, T Chen, R Redd, ... Neuro-oncology 20 (8), 1034-1043, 2018 | 122 | 2018 |
| Bayesian adaptive randomized trial design for patients with recurrent glioblastoma L Trippa, EQ Lee, PY Wen, TT Batchelor, T Cloughesy, G Parmigiani, ... Journal of Clinical Oncology 30 (26), 3258, 2012 | 119 | 2012 |
| Bayesian adaptive randomized trial design for patients with recurrent glioblastoma L Trippa, EQ Lee, PY Wen, TT Batchelor, T Cloughesy, G Parmigiani, ... Journal of Clinical Oncology 30 (26), 3258, 2012 | 119 | 2012 |
| A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials JMS Wason, L Trippa Statistics in medicine 33 (13), 2206-2221, 2014 | 117 | 2014 |
| Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab OM Filho, G Viale, S Stein, L Trippa, DA Yardley, IA Mayer, VG Abramson, ... Cancer discovery 11 (10), 2474-2487, 2021 | 115 | 2021 |
| Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ... Nature communications 11 (1), 2996, 2020 | 115 | 2020 |
| Cross-study validation for the assessment of prediction algorithms C Bernau, M Riester, AL Boulesteix, G Parmigiani, C Huttenhower, ... Bioinformatics 30 (12), i105-i112, 2014 | 112 | 2014 |
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 106 | 2021 |
| Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-negative metastatic breast cancer: A randomized … SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, ... JAMA oncology 6 (10), 1598-1605, 2020 | 103 | 2020 |
| Hazards of hazard ratios—deviations from model assumptions in immunotherapy BM Alexander, JD Schoenfeld, L Trippa New England Journal of Medicine 378 (12), 1158-1159, 2018 | 89 | 2018 |
| HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. O Metzger Filho, G Viale, L Trippa, T Li, DA Yardley, IA Mayer, ... Journal of Clinical Oncology 37 (15_suppl), 502-502, 2019 | 87 | 2019 |
